Use of nonhormonal natural products in the prevention and complex treatment of fibrocystic breast disease
According to WHO (1984), mastopathy is a fibrocystic disease (FCD) characterized by the imbalance of epithelial and connective tissue in the breast and a wide range of proliferative and regressive changes. Clinical practitioners commonly use the classification proposed by N.I. Rozhkova in 1983.
Main Authors: | D. M. Magomethanova, Z. S. Zydieva, G. S. Bоgdanova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2013-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/954 |
Similar Items
-
CURRENT POTENTIALITIES OF THERAPY FOR FIBROCYSTIC DISEASE
by: I. V. Vysotskaya
Published: (2014-09-01) -
Practical guidelines for drug correction of diffuse dyshormonal dysplasia of the breast
by: I. V. Vysotskaya, et al.
Published: (2014-07-01) -
Therapy for fibrocystic breast disease in patients with uterine myoma
by: N. V. Kulagina
Published: (2014-08-01) -
Fibrozno-kistoznaya mastopatiya
by: T T Tagieva
Published: (2005-06-01) -
Neoadjuvant treatment for breast cancer
by: V. F. Semiglazov, et al.
Published: (2014-07-01)